Short answer
Oruka Therapeutics, Inc. (ORKA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$50M
- −65.0% YoY · −21.3% QoQ
Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) Q3 2026 10-Q on SEC EDGAR. USD.
Oruka Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved or sales revenue generated
- Net loss $50.0M vs $30.3M YoY, operating margin not disclosed
- R&D expenses $53.7M vs $29.0M, external costs $38.3M vs $15.6M
- Cash, equivalents and securities $1.2B; operating cash use $101.0M for nine months
- Financing $830.4M, including $658.3M offering proceeds and $161.4M ATM proceeds
- Outlook: Phase 3 ORKA-001 trials planned first half 2027; losses expected to increase substantially
Risk Factors
- Newly added manufacturing risk: BIOSECURE Act enacted December 2025, potentially restricting WuXi Biologics and forcing costlier supplier transitions
- Most materially updated regulatory risk: FDA disruption following Trump administration layoffs and policy changes, potentially delaying reviews and clinical-trial authorizations
- Clinical development risk: ORKA-001 Phase 3 expected first half of 2027, while Phase 2a and Phase 2b trials remain ongoing
- Financial risk: April 2026 equity offering raised $658.3 million net, while August 2026 ATM capacity increased to $500.0 million, creating dilution risk
- Operational risk: Sole-source supply for ORKA-001 and ORKA-002 leaves development vulnerable to supplier disruption
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oruka Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.